Találati lista | Tudóstér

001-es BibID:	BIBFORM097366
035-os BibID:	(WoS)000773543201173
Első szerző:	Molnár Szabolcs (szülész-nőgyógyász szakorvos)
Cím:	The role of neoadjuvant chemotherapy in the treatment of iiic-iva stage epithelial ovarian cancer : a single center experience / Molnár Szabolcs, Vas Lilla Éva, Maka Eszter, Lampé Rudolf, Vida Beáta, Krasznai Zoárd
Dátum:	2021
ISSN:	1048-891X
Megjegyzések:	Introduction/Background* Ovarian cancer is the 7th most common malignancy among women and the leading cause of gynecologic cancer death. The most important prognostic factor of the disease is optimal debulking surgery (R0) with no macroscopic residual disease. Achieving optimal result is a challenging duty in advanced stage (FIGO IIIC-IV). Based on previous studies neoadjuvant chemotherapy (NAC) can help to improve the optimally debulked ratio of this popu- lation with non-inferior survival outcome. The aim of our study was to evaluate the effectiveness of NAC among pri- marily inoperable patients. The focus was not only on sur- vival outcome but on cost effectiveness (need for transfusion, hospitalization, ICU admission, medication demand, etc.). Methodology Between 2015-2018 112 debulking surgeries were performed on stage FIGO IIIC-IV ovarian cancer patients. The cases were divided into potentially operable and inoperable group based on preoperative imaging, tumor marker levels according to our institutional protocol. In spe- cial situation where operability was not obvious, diagnostic laparoscopy was done to categorize patients. The peri-, intra-, postoperative reports and survival data was collected. Result(s)* Complete tumor reduction was performed in 63 cases while in 49 cases only partial tumor reduction was achieved. Median progression-free survival did not differ sig- nificantly between patients who underwent primary or interval debulking surgery (PDS = 12 months, IDS = 11.2 months, p = 0.264). The rate of R0 resection was higher after NAC, but not significantly (37.9% vs. 54.2%, p = 0.179). There was no significant difference in survival of patients who suc- cessfully underwent complete tumor reduction, despite the fact that the "inoperable" group treated with NAC had a worse prognosis (p = 0.264). The cost-effectiveness was comparable between groups, the hospital stay and transfusion demand was favourable in neoadjuvant group. Conclusion* The rate of optimal tumor reduction can be improved not only by increasing radicality but also by apply- ing appropriate patient selection criteria. Neoadjuvant treat- ment according to the current recommendations is applicable in the inoperable group, in accordance with the protocol we use. The survival data of patients who have undergone com- plete tumor reduction after NAC was not inferior to those who went through primary debulking.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idézhető absztrakt folyóiratcikk petefészek daganat neoadjuváns kemoterápia debulking műtét progressziómentes túlélés
Megjelenés:	International Journal Of Gynecological Cancer. - 31 : Suppl. 3 (2021), p. A247. -
További szerzők:	Vas Lilla Éva Maka Eszter (1988-) (szülész-nőgyógyász rezidens) Lampé Rudolf (1983-) (szülész-nőgyógyász) Vida Beáta (1994-) (szülészet-nőgyógyászat) Krasznai Zoárd Tibor (1973-) (szülész-nőgyógyász, gyermeknőgyógyász)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM124149
Első szerző:	Orosz Mónika (Szülész-nőgyógyász)
Cím:	Endocrine Characteristics and Obstetric Outcomes of PCOS Patients with Successful IVF and Non-IVF Pregnancies / Orosz Mónika, Borics Fanni, Rátonyi Dávid, Krasznai Zoárd Tibor, Vida Beáta, Herman Tünde, Csehely Szilvia, Jakab Attila, Lukács Luca, Lampé Rudolf, Deli Tamás
Dátum:	2024
ISSN:	2077-0383
Megjegyzések:	Background/Objective: Infertility affects an estimated 40?50% of women with polycystic ovary syndrome (PCOS), the leading cause of anovulatory infertility, but only a small proportion of the patients require in vitro fertilization (IVF) therapy. Both PCOS and IVF are associated with an increased risk of obstetric complications. To compare preconception endocrine profiles and symptoms, as well as obstetric outcomes of PCOS patients who achieved successful pregnancies with and without IVF treatment. Methods: A single-center retrospective cohort study was conducted. Data spanning from 2012 to 2019 were compiled from patients with PCOS who visited the Gynecologic Endocrinology Unit and the Infertility Unit at the Department of Obstetrics and Gynecology, University of Debrecen. Patients diagnosed with PCOS who had had at least one successful delivery beyond the 23rd gestational week at the department were eligible for inclusion in the study. Results: Fifteen percent of the 206 pregnancies leading to successful deliveries of 232 newborns in our cohort conceived with IVF. A one year increase in the maternal age increased the odds of being in the IVF group by 22% (OR: 1.222, 95% confidence interval, CI: 1.11?1.35, p < 0.001). Baseline DHEAS and androstenedione levels were significantly lower in the IVF group as compared to the non-IVF group: 1 ?mol/L increase in the DHEAS level decreased the odds of being in the IVF group by 18% (OR: 0.82, 95% CI: 0.66?1.01, p = 0.06), and 1 ?g/L increase in the serum androstenedione concentration decreased the same odds by 42% (OR: 0.58, 95% CI: 0.33?1.02, p = 0.056). DHEAS levels <6.5 ?mol/L had an OR 3.86 (95% CI 1.10?13.50, p = 0.04) and LH/FSH ratio <1.3 had an OR 3.58 (95% CI 1.18?10.81, p = 0.03) for being in the IVF group. The birth weight (3069 ? 683 g vs. 3362 ? 638 g, p = 0.02) and the gestational age (37.23 ? 2.55 vs. 38.54 ? 2.28 weeks, p = 0.004) were significantly lower in the IVF group, but in the singleton subgroups, no significant differences could be found. Birth weight percentiles showed no significant difference in either subgroup. In the IVF group, both preterm delivery (29% vs. 8.3%, OR 4.53, 95% CI 1.75?11.70, p = 0.002; singleton subgroup: 17.4% vs. 6.3%, OR 3.12, 95% CI 0.89?10.92, p = 0.07) and cesarean section (71% vs. 43.2%, OR 3.22, 95% CI 1.40?7.40, p = 0.006; singleton subgroup: 65.2% vs. 42.4%, OR 2.55, 95% CI 1.02?6.35, p = 0.04) were more frequent than in the non-IVF group. Gestational diabetes and preeclampsia were not significantly different in the IVF and non-IVF groups. Conclusions: In PCOS patients with successful pregnancies, those who conceive with IVF seem to be different in their baseline hormone levels and symptoms from the non-IVF group. Adverse obstetric outcomes are more common in the IVF group, and some of these differences persist when adjusting for singleton pregnancies and maternal age, too.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk polycystic ovary syndrome pregnancy complications in vitro fertilization pre-pregnancy hormone levels obstetric outcomes androgen levels
Megjelenés:	Journal of Clinical Medicine. - 13 : 18 (2024), p. 1-13.-
További szerzők:	Borics Fanni Rátonyi Dávid (1996-) (Szülész-nőgyógyász) Krasznai Zoárd Tibor (1973-) (szülész-nőgyógyász, gyermeknőgyógyász) Vida Beáta (1994-) (szülészet-nőgyógyászat) Herman Tünde (1979-) (orvos) Csehely Szilvia (1990-) (szülész-nőgyógyász szakorvos) Jakab Attila (1964-) (szülész-nőgyógyász, endokrinológus) Lukács Luca (1995-) (hallgató) Lampé Rudolf (1983-) (szülész-nőgyógyász) Deli Tamás (1979-) (szülész-nőgyógyász, endokrinológus szakorvos)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: